Shireman & Shireman Research

OXIS International develops technologies and products used for the research, diagnosis, treatment and prevention of diseases caused by the oxidative stress associated with damage from free radical and reactive oxygen species. The company offers more than 80 research products that are used in testing for oxidative, antioxidant, nitrosative and inflammatory biomarkers, which are thought to play a central role in many human degenerative diseases, including cancer, diabetes, atherosclerosis, stroke, Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis. The company holds the rights to three therapeutic classes of compounds in the area of oxidative stress and has focused commercialization programs in clinical cardiovascular markers, including myeloperoxidase and glutathione peroxidase, as well as a highly potent antioxidant, ergothioneine. OXIS International is headquartered in Portland, Ore.

The Center for Culinary Development in San Francisco, CA is a hub for culinary innovation and experimentation. They provide a space for chefs and food industry professionals to collaborate and develop new recipes and products. With state-of-the-art facilities and a team of experienced culinary experts, the Center for Culinary Development is dedicated to pushing the boundaries of food and flavor. Their focus on research and development helps clients bring unique and delicious products to market. Generated from their business information

Potrero Hill Therapeutics is a biopharmaceutical company based in San Francisco, founded by a team of experienced professionals specializing in early-stage drug discovery and development. The company focuses on discovering and developing novel therapeutics, leveraging its resources to identify promising preclinical opportunities with valid scientific foundations and strong market potential. With a robust business model and a skilled leadership team, Potrero Hill Therapeutics efficiently utilizes resources and capital to generate strong intellectual property. This strategic approach enables the company to achieve early clinical proof of concept and pursue successful exits in the biopharmaceutical sector. Generated from the website